Healthcare Industry News:  neurostimulation 

Devices FDA

 News Release - April 12, 2006

Neuroscience Therapy Corp. Receives FDA Approval to Begin Marketing P-Stim in U.S.

LAS VEGAS, NV, April 12 (HSMN NewsFeed) - Neuroscience Therapy Corp. (OTC: NPYC ) announced today that it has received FDA approval to begin marketing its primary device P-Stim in the United States.

P-Stim, which has been deemed highly successful in treating pain in thousands of patients in Europe, is now permitted to be marketed in the U.S. where it is expected to produce a substantial amount of revenue for Neuroscience Therapy.

It was stated by the National Institute of Health: "Pain is a critical national health problem. It is the most common reason for medical appointments, nearly 40 million visits annually, and costs this country over $100 billion each year in health care and lost productivity."

Neuroscience Therapy is now able to enter the multi-billion dollar market for pain in the U.S. and plans to begin a nationwide campaign to promote P-Stim.

President and CEO Dr. Randolph A. Turpin of Neuroscience Therapy said:

"I'm very proud of our team for enabling Neuroscience Therapy to get to this point. We are now in an ideal position to begin making revenues in this multi-billion dollar market."

About Neuroscience Therapy Corporation:

Neuroscience Therapy Corp. is incorporated in the state of Washington with operations located in Southern California. It holds the rights to a new, safe and innovative technology to relieve pain. Its product portfolio consists of two complementary products: the P-Stim(TM) Electro Stimulation Device and the Multi-Point(TM) Stylus. These products have no known side effects, unlike many pharmaceutical pain relievers. The neurostimulation market is in its infancy and could reach several billion dollars in sales. The Company is working toward being a leader in this market. For more information about the Neuroscience Therapy Corp., visit: www.neurosciencetherapy.com

The information contained in this press release may include forward-looking statements. Forward-looking statements usually contain the words "estimate," "anticipate," "believe," "expect," or similar expressions that involve risks and uncertainties. These risks and uncertainties include the Company's uncertain profitability, need for significant capital, uncertainty concerning market acceptance of its products, competition, limited service and manufacturing facilities, dependence on technological developments and protection of its intellectual property. The Company's actual results could differ materially from those discussed herein.


Source: Neuroscience Therapy Corporation

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.